Prosecution Insights
Last updated: April 19, 2026
Application No. 17/913,292

Solid Dispersions of Amorphous 3,4-Diphenyl-4,5-Dihydro-1H-Pyrazole Derivatives, Compositions Comprising them and Uses Thereof as Cannabinoid CB1 Receptor Inhibitors

Non-Final OA §112
Filed
Sep 21, 2022
Examiner
SAEED, KAMAL A
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Novo Nordisk A/S
OA Round
1 (Non-Final)
84%
Grant Probability
Favorable
1-2
OA Rounds
2y 3m
To Grant
93%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allow Rate
1007 granted / 1194 resolved
+24.3% vs TC avg
Moderate +9% lift
Without
With
+9.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
16 currently pending
Career history
1210
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
11.5%
-28.5% vs TC avg
§102
9.4%
-30.6% vs TC avg
§112
19.3%
-20.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1194 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1, 9, 17-19, 21, 22, 27, 30-32, 34, 36, 38, 41, 43, 44, 46 and 51-55 are currently pending in this Application. Claims 34, 36, 38, 41, 43, 44, 46 and 51-55 are withdrawn from further consideration by the Examiner, 37 C.F.R. § 1.142(b), as being drawn to a non-elected invention. Information Disclosure Statement Applicant’s Information Disclosure Statements, filed on 05/31/2023; 06/11/2024; and 06/02/2025 have been considered. Please refer to Applicant’s copies of the 1449 submitted herewith. Response to Restriction Applicants’ election, with traverse, the invention of Group I, claims 1, 9, 17-19, 21, 22, 27 and 30-32 drawn to a product of Formula, PNG media_image1.png 240 360 media_image1.png Greyscale and the specific compound, PNG media_image2.png 222 330 media_image2.png Greyscale , in response filed June 02, 2025 and July 17, 2025 is acknowledged. Therefore, the restriction requirement is considered proper and is maintained. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i). The scope of the invention of the elected subject matter is as follows: The elected species was found to be free of prior art and therefore, the scope of the examined subject matter was expanded to full scope of the elected claims. Therefore, the election of species requirement mailed on May 06, 2025 is hereby withdrawn. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. The primary purpose of this requirement of definiteness of claim language is to ensure that the scope of the claims is clear so the public is informed of the boundaries of what constitutes infringement of the patent. A secondary purpose is to provide a clear measure of what applicants regard as the invention so that it can be determined whether the claimed invention meets all the criteria for patentability and whether the specification meets the criteria of 35 U.S.C. 112, first paragraph with respect to the claimed invention.", (see MPEP § 2173). Claims 1, 9, 17-19, 21, 22, 27 and 30-32 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance; Claim 1, in several instances use the term “preferably” renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). It is suggested that Applicants delete the term “preferably” from the claim. Claim 9, in several instances use the term “preferably” and “e.g” renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). It is suggested that Applicants delete the term “preferably” from the claim. Claim 22, in several instances use the term “preferably” and “e.g” a renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). It is suggested that Applicants delete the term “preferably” from the claim. Claim 27, in several instances use the term “preferably” and “e.g” renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). It is suggested that Applicants delete the term “preferably” from the claim. Allowable Subject Matter Claims 1, 9, 17-19, 21, 22, 27 and 30-32 would be allowable once the 112 rejections outlined above have been overcome. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAMAL A SAEED, Ph.D. whose telephone number is (571) 272-0705. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mr. Joseph K. McKane, can be reached at (571) 272-0699. Communication via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise requires a signature, may be used by applicant and should be addressed to [Symbol font/0x5B]joseph.mckane@uspto.gov[Symbol font/0x5D]. All Internet e-mail communications will be made of record in the application file. PTO employees will not communicate with applicant via Internet e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive data could be identified unless there is of record an express waiver of the confidentiality requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG 89. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR only. For more information about the pair system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197. /Kamal A Saeed/ Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Sep 21, 2022
Application Filed
Jun 02, 2025
Response after Non-Final Action
Oct 31, 2025
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600699
THIOSEMICARBAZATES AND USES THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12599582
PYRROLE COMPOUNDS
2y 5m to grant Granted Apr 14, 2026
Patent 12595233
THIOSEMICARBAZATES AND USES THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12590059
PROCESS FOR THE PRODUCTION OF LEVETIRACETAM
2y 5m to grant Granted Mar 31, 2026
Patent 12590068
CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR
2y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
84%
Grant Probability
93%
With Interview (+9.0%)
2y 3m
Median Time to Grant
Low
PTA Risk
Based on 1194 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month